#SFHS2612117AFrance Adds LYNQUERA LP Methylphenidate Medicines to Reimbursable Drug List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France adds three LYNQUERA LP prolonged-release methylphenidate products to the list of medicines reimbursed by health insurance. The covered strengths are 18 mg, 36 mg, and 54 mg packs supplied by Exeltis Santé. Reimbursement is limited to ADHD treatment for children aged 6 and older and adults, as part of broader care, when non-drug measures are not enough. Treatment must be started and supervised by a specialist in ADHD care, such as a pediatrician, child and adolescent psychiatrist, or adult psychiatrist.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds LYNQUERA LP 18 mg, 36 mg, and 54 mg prolonged-release methylphenidate to France’s reimbursable medicines list
- Limits reimbursement to ADHD treatment in children aged 6 and older and adults when corrective measures alone are insufficient
- Requires treatment to be started and supervised by a specialist in ADHD care
Obligations
What this law requires
Health insurance reimbursement for LYNQUERA LP prolonged-release methylphenidate 18 mg, 36 mg, and 54 mg products supplied by Exeltis Santé is limited to treatment of ADHD in children aged 6 years and older, as part of comprehensive care, when corrective non-drug measures alone are insufficient.
Health insurance reimbursement for LYNQUERA LP prolonged-release methylphenidate 18 mg, 36 mg, and 54 mg products supplied by Exeltis Santé is limited to treatment of ADHD in adults, as part of comprehensive care, when corrective non-drug measures alone are insufficient.
Treatment with reimbursable LYNQUERA LP for ADHD must be initiated and supervised by a physician specialized in ADHD treatment, such as a pediatric specialist, child and adolescent psychiatrist, or adult psychiatrist.